DUPIXENT WAS STUDIED IN ONE OF THE LARGEST CRSwNP
BIOLOGICS TRIAL PROGRAMS TO DATE

Results showed improvement in key areas for adult patients with CRSwNP

These trials included 724 adults with uncontrolled chronic rhinosinusitis with nasal polyps (CRSwNP).

Can improve the ability to smell
in as little as 3 days
a

Significant reduction
in nasal polyp size

Reduced nasal congestion by as
much as 50%
b

83% fewer patients required
nasal polyp surgery
c

 

a Individual results may vary.

b For patients on DUPIXENT 300 mg in 24-week and a 52-week clinical trial vs 17% for placebo group.

c Compared to placebo + standard of care (SOC).

Patients on DUPIXENT can experience an improvement in the ability to smell in as little as 3 days. Patients also saw relief at Week 24 and Week 52 of treatment. Click the tabs below to view the results of the SINUS-52 trial (n=295).

Before treatment with DUPIXENT

Nasal polyps and nasal congestion
are present

DAY 3 OF TREATMENT with DUPIXENT

Some patients saw improvement in
nasal
congestion and ability to smell as
early as day 3

Analysis on Day 3 was not evaluated during the clinical trial,
and any results at Day 3 may be due to chance.

WEEK 4 OF TREATMENT with DUPIXENT

Nasal polyps begin to show
measurable shrinkage

WEEK 24 OF TREATMENT with DUPIXENT

Significant
shrinkage:

28%

improvement in nasal polyp burden

vs. 2% worsening
with placebo

Less nasal
congestion:

47%

improvement in nasal
congestion

vs. 16% with placebo

Based on analysis on week 24 during SINUS-52 clinical trial of
adult patients receiving DUPIXENT (n=295) vs placebo (n=153).

WEEK 52 OF TREATMENT with DUPIXENT

Significant
shrinkage:

37%

improvement in nasal polyp burden

vs. 5% worsening
with placebo

Less nasal
congestion:

56%

improvement in nasal congestion

vs. 15% with placebo

Based on analysis on week 52 during SINUS-52 clinical trial of
adult patients receiving DUPIXENT (n=295) vs placebo (n=153).

Select a time period
to see the results.

All adult patients were on background intranasal corticosteroids.

Individual Results May Vary.
Images are illustrative only.

The most common side effects include:

  • Injection site reactions
  • Eye and eyelid inflammation, including
    redness, swelling, and itching
  • High count of a certain white blood
    cell (eosinophilia)
  • Gastritis
  • Joint pain (arthralgia)
  • Trouble sleeping (insomnia)
  • Toothache

View the possible side effects of DUPIXENT in patients with uncontrolled chronic rhinosinusitis with nasal polyps.
The use of DUPIXENT in patients 12-17 years of age is supported by the efficacy and safety results from studies done in adults with CRSwNP.

HAVE A PRODUCTIVE CONVERSATION
WITH YOUR DOCTOR

Personalize your doctor discussion guide

Our goal is for you or your loved one to get the most out of your visit to the doctor. Use our doctor discussion guide to help personalize your next visit.

Less Nasal Polyps. More You.

With DUPIXENT, you can do more of what matters most

In clinical studies, utilizing a symptom measurement tool, people taking DUPIXENT saw a meaningful improvement in their nasal polyps symptoms, which included, but were not limited to:

  • Nasal blockage
  • Facial pain/pressure
  • Difficulty falling asleep
  • Fatigue
  • Decreased sense of smell/taste

The relationship between DUPIXENT and its effect on individual symptoms was studied by a multi-symptom questionnaire, but not definitively proven. Ask your doctor how DUPIXENT may help.

 

Find a specialist who treats Nasal Polyps

Sometimes your doctor may need to partner with a specialist in diagnosing and treating your CRSwNP. Your nasal polyps specialists have access to tools your provider may not have.

The DUPIXENT MyWay® Copay Card may help eligible patients cover the out-of-pocket cost of DUPIXENT. Terms & Restrictions Apply.

FREQUENTLY ASKED QUESTIONS

The effectiveness and safety of DUPIXENT has been studied in the largest clinical trials to date for CRSwNP with 724 adults with uncontrolled chronic rhinosinusitis with nasal polyps (CRSwNP).

  • In both studies, DUPIXENT was proven to help patients breathe better by relieving nasal congestion and reducing the size of nasal polyps compared to placebo group.

Patients enrolled in these studies included subjects with CRSwNP regardless of whether they had prior sino-nasal surgery or treatment with, or who were ineligible to receive or were intolerant to, systemic corticosteroids in the past 2 years. Patients with chronic rhinosinusitis without nasal polyps were not included in these trials.

In clinical trials, DUPIXENT reduced nasal congestion and nasal polyp size in adult patients with uncontrolled chronic rhinosinusitis with nasal polyps (CRSwNP).

In clinical studies, utilizing a symptom measurement tool, adults taking DUPIXENT saw less nasal congestion in as little as 2 days. Learn more about these trials and how DUPIXENT may help treat your symptoms.

In clinical trials, DUPIXENT reduced nasal congestion and nasal polyp size in adult patients with uncontrolled chronic rhinosinusitis with nasal polyps (CRSwNP) and improved the ability to smell.

In clinical studies, utilizing a symptom measurement tool, adults taking DUPIXENT saw an improved ability to smell in as little as 3 days.